NEW YORK (GenomeWeb News) – Epigenomics said today that it has signed up the biomedical distributor Dateks to market its colorectal cancer test in Turkey.
Epigenomics said that Dateks will market the Epi proColon, a DNA methylation-based test that detects colorectal cancer in blood plasma by identifying the Septin 9 biomarker.
Even though Cancer Early Diagnosis and Screening Centers have been set up in most provinces and the Turkish Ministry of Health has implemented CRC screening standards, screening is still low, Epigenomics said. The company said that this has "severe consequences as colorectal cancer is highly curable when detected at an early [and] still localized stage."
Dateks CEO Süha Dere said in a statement that this blood test is "as simple clean solution" that "can be performed at any time and it does not require any preparation of the screened individual."
"We believe this test can help significantly to drive acceptance of colorectal cancer early detection in the Turkish population," Dere added.
Epigenomics currently markets the Epi proColon test directly in Germany, Austria, and Switzerland.